Astria Therapeutics, Inc. ATXS
We take great care to ensure that the data presented and summarized in this overview for Astria Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ATXS
View all-
Perceptive Advisors LLC New York, NY6.49MShares$81.5 Million0.1% of portfolio
-
Vestal Point Capital, LP New York, NY4.96MShares$62.3 Million1.63% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.11MShares$51.6 Million5.98% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$44.7 Million5.59% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$44.2 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.03MShares$38.1 Million0.01% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.76MShares$34.7 Million2.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.64MShares$33.2 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY2.46MShares$30.9 Million2.7% of portfolio
-
Jpmorgan Chase & CO New York, NY1.68MShares$21.1 Million0.0% of portfolio
Latest Institutional Activity in ATXS
Top Purchases
Top Sells
About ATXS
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Insider Transactions at ATXS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 01
2024
|
Christopher Morabito Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$130,000
$13.59 P/Share
|
|
Apr 01
2024
|
Christopher Morabito Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$30,000
$3.87 P/Share
|
|
Feb 01
2024
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
2,481,350
+33.74%
|
$29,776,200
$12.09 P/Share
|
|
Jan 29
2024
|
Christopher Morabito Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,200
-100.0%
|
$101,200
$11.15 P/Share
|
|
Jan 29
2024
|
Christopher Morabito Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,200
+50.0%
|
$27,600
$3.87 P/Share
|
|
Jan 26
2024
|
Christopher Morabito Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
800
-100.0%
|
$8,800
$11.02 P/Share
|
|
Jan 26
2024
|
Christopher Morabito Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
800
+50.0%
|
$2,400
$3.87 P/Share
|
|
Dec 21
2023
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
740,000
+23.62%
|
$4,440,000
$6.2 P/Share
|
|
Oct 16
2023
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
1,074,608
+24.66%
|
$6,447,648
$6.51 P/Share
|
|
Dec 19
2022
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
908,265
+46.66%
|
$9,990,915
$11.01 P/Share
|
|
Nov 19
2021
|
Andrew Komjathy Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
100
+50.0%
|
$600
$6.7 P/Share
|
|
Sep 20
2021
|
Jonathan Violin Director |
BUY
Other acquisition or disposition
|
Direct |
263,321
+50.0%
|
-
|
|
Sep 20
2021
|
Jonathan Violin Director |
SELL
Other acquisition or disposition
|
Indirect |
263,321
-100.0%
|
-
|